The stock of QIAGEN N.V. (NYSE:QGEN) hit a new 52-week high and has $40.32 target or 8.00% above today’s $37.33 share price. The 6 months bullish chart indicates low risk for the $8.48 billion company. The 1-year high was reported on Jun, 13 by Barchart.com. If the $40.32 price target is reached, the company will be worth $678.32 million more. The stock increased 0.30% or $0.11 during the last trading session, reaching $37.33. About 1.10 million shares traded or 32.10% up from the average. QIAGEN N.V. (NYSE:QGEN) has risen 10.41% since June 13, 2017 and is uptrending. It has underperformed by 2.16% the S&P500. Some Historical QGEN News: ; 06/03/2018 QIAGEN announces 20-F annual report filing for 2017 results; 28/03/2018 – PRWeb: System Biosciences Announces New Non-Exclusive License of ExoQuick® Technology to QIAGEN; 20/04/2018 – Qiagen Presenting at Bank of America Conference May 16; 09/04/2018 – PANGAEA ONCOLOGY SA PANGO.MC SAYS SIGNS STRATEGIC AGREEMENT IN ONCOLOGICAL DIAGNOSIS WITH GERMAN DIAGNOSTIC MULTINATIONAL QIAGEN; 10/04/2018 – Qiagen Presenting at Deutsche Bank Health Care Conference May 8; 12/03/2018 – QIAGEN and Natera Partner to Develop Cutting-Edge Genetic Testing Assays for Use on QlAGEN’s GeneReader NGS System; 20/04/2018 – QIAGEN Announces FDA Approval Of PartoSureTM; 09/04/2018 – PANGAEA ONCOLOGY SA PANGO.MC – AS FIRST STEP CO TO PERFORM QIAGEN TECHNOLOGY VALIDATION TASKS FOR DIAGNOSIS OF VARIOUS TUMOR TYPES; 04/05/2018 – QIAGEN NV QIA.DE : CFRA RESEARCH RAISES TARGET PRICE TO EUR 29 FROM EUR 27; 12/04/2018 – QIAGEN Launches AdnaTest Liquid Biopsy Kits in Prostate and Lung Cancer
Among 8 analysts covering Collegium Pharmaceutical Inc (NASDAQ:COLL), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Collegium Pharmaceutical Inc had 19 analyst reports since February 19, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Monday, February 12 by Piper Jaffray. Cantor Fitzgerald initiated the stock with “Buy” rating in Monday, June 11 report. The stock has “Buy” rating by Jefferies on Friday, July 14. The stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has “Buy” rating given on Friday, June 9 by Needham. Janney Capital maintained Collegium Pharmaceutical, Inc. (NASDAQ:COLL) rating on Friday, June 9. Janney Capital has “Buy” rating and $2500 target. The firm has “Buy” rating given on Monday, June 12 by Jefferies. William Blair initiated Collegium Pharmaceutical, Inc. (NASDAQ:COLL) rating on Friday, February 19. William Blair has “Outperform” rating and $35 target. Janney Capital maintained Collegium Pharmaceutical, Inc. (NASDAQ:COLL) rating on Monday, November 6. Janney Capital has “Buy” rating and $21.0 target. The firm earned “Buy” rating on Thursday, December 14 by Piper Jaffray. Piper Jaffray maintained the stock with “Buy” rating in Tuesday, July 25 report. See Collegium Pharmaceutical, Inc. (NASDAQ:COLL) latest ratings:
11/06/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $40.0000 Initiate
12/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
11/02/2018 Broker: Jefferies Rating: Buy New Target: $32.0 Maintain
23/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
14/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $23.0 Maintain
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The company has market cap of $886.57 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain. It currently has negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.
The stock increased 0.34% or $0.09 during the last trading session, reaching $26.83. About 91,210 shares traded. Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has risen 169.07% since June 13, 2017 and is uptrending. It has outperformed by 156.50% the S&P500. Some Historical COLL News: ; 27/03/2018 – PERNIX THERAPEUTICS HOLDINGS – EXPECTS TO RESUME DISTRIBUTION OF 20 MG DOSAGE STRENGTH OF ZOHYDRO ER (HYDROCODONE BITARTRATE) WITH BEADTEK ON MARCH 28; 19/03/2018 – COLLEGIUM NAMES SHIRLEY KUHLMANN AS GENERAL COUNSEL; 09/05/2018 – COLLEGIUM – BELIEVE EXISTING CASH RESOURCES, WITH EXPECTED CASH INFLOWS TO FUND OPERATING EXPENSES, DEBT SERVICE, CAPEX NEEDS AT LEAST INTO 2020; 07/03/2018 – COLLEGIUM PHARMACEUTICAL – BELIEVE EXISTING CASH RESOURCES WILL FUND OPER EXPENSES, DEBT SERVICE AND CAPEX REQUIREMENTS INTO 2020; 10/05/2018 – Collegium Closes Above 50-Day Moving Average: Technicals; 20/04/2018 – COLLEGIUM TO HOST CONFERENCE CALL TO DISCUSS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE; 07/05/2018 – Collegium at Deutsche Bank Health Care Conference Tomorrow; 04/04/2018 – Collegium Presenting at Conference Apr 10; 09/04/2018 – Collegium Presenting at Conference Tomorrow; 09/05/2018 – Collegium Pharmaceutical 1Q Loss/Shr 57c
More notable recent Collegium Pharmaceutical, Inc. (NASDAQ:COLL) news were published by: Benzinga.com which released: “Cantor Fitzgerald Out Bullish On Collegium As ‘Leading Company’ In Pain Management” on June 12, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on June 12, 2018, Schaeffersresearch.com published: “2 Healthcare Stocks Expected to Skyrocket” on June 12, 2018. More interesting news about Collegium Pharmaceutical, Inc. (NASDAQ:COLL) were released by: Globenewswire.com and their article: “Collegium Announces CEO Succession” published on June 04, 2018 as well as Benzinga.com‘s news article titled: “Brandon Folkes” with publication date: June 12, 2018.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company has market cap of $8.48 billion. It offers sample technologies for plasmid deoxyribonucleic acid purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technology solutions. It has a 162.3 P/E ratio. The firm provides Ingenuity Variant Analysis, a cloud platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products.
Analysts await QIAGEN N.V. (NYSE:QGEN) to report earnings on July, 26. They expect $0.32 EPS, up 6.67% or $0.02 from last year’s $0.3 per share. QGEN’s profit will be $72.68 million for 29.16 P/E if the $0.32 EPS becomes a reality. After $0.26 actual EPS reported by QIAGEN N.V. for the previous quarter, Wall Street now forecasts 23.08% EPS growth.